Traphaco (TRA) Fined VND 160 Million by Drug Administration for Manufacturing Violations

Overview

Traphaco (HOSE: TRA), one of Vietnam’s largest listed pharmaceutical manufacturers, has been fined VND 160 million by the Drug Administration of Vietnam under the Ministry of Health for three administrative violations in drug manufacturing. The decision covers unapproved changes to registered drug dossiers and the use of talc outside approved production and testing procedures. The penalty is small in absolute terms but arrives alongside a documented history of tax-related sanctions, putting regulatory compliance at the center of the TRA investment case.

Key Facts

• Total fine: VND 160 million (approximately USD 6,400), issued by the Drug Administration of Vietnam under the Ministry of Health.
• Violation 1: Producing multiple batches of Piracetam 400mg hard capsules (registration no. 893110454724) with minor changes versus the approved dossier, without prior approval — fined VND 40 million.
• Violation 2: Producing batches of Piracetam 400mg, Methorphan cough medicine (VD-19625-13), Nostravin (VD-24976-16) and Loratadin 10mg (VD-18488-13) with major changes versus the approved dossier, without approval — fined VND 60 million.
• Violation 3: Using Luzenac 00 talc, declared by its manufacturer for both pharmaceutical and food use, in drug production outside the approved manufacturing and testing procedures — fined VND 60 million.
• The Drug Administration identified two aggravating factors per violation — repeated administrative violations and large-scale, high-volume production — and applied the maximum penalty in each bracket.
• The decision cites Decree No. 90/2026/ND-CP dated 30 March 2026 on administrative penalties in healthcare; no additional sanctions or remedial measures were imposed.
• Prior tax penalties: nearly VND 1 billion in 2018, over VND 2.4 billion in 2023, and approximately VND 3.3 billion in February 2026.

What Happened

The Drug Administration of Vietnam issued an administrative penalty decision against Traphaco, headquartered at 75 Yen Ninh Street, Ba Dinh Ward, Ha Noi. The company was found to have manufactured multiple batches of Piracetam 400mg hard capsules with minor deviations from its approved registration dossier, and multiple batches of Piracetam 400mg, Methorphan, Nostravin and Loratadin 10mg with major deviations, in each case without the required regulatory approval for the changes. It also used Luzenac 00 talc — a material declared by its producer for both pharmaceutical and food applications — in drug production in a manner inconsistent with the approved manufacturing and testing procedures.

The Drug Administration treated each violation as carrying two aggravating circumstances: repeated administrative violations and violations of large scale and volume. Because two or more aggravating factors applied, the maximum fine within each penalty bracket was imposed, totaling VND 160 million. The decision, issued under Decree 90/2026/ND-CP, does not impose supplementary penalties or require remedial measures. The article notes this is not Traphaco’s first regulatory action: the company was penalized and assessed back taxes by the Ha Noi Tax Department in 2018, again in 2023 following 2021-2022 inspections, and most recently in February 2026 for value-added, corporate income and personal income tax violations plus late payment interest.

Market Context

TRA trades on the Ho Chi Minh Stock Exchange (HOSE) and closed at VND 36,000 in the most recent price context. The fine itself is immaterial relative to Traphaco’s revenue and market capitalization, and the decision imposes no product recalls, license suspensions or remedial requirements. The relevant market signal is qualitative rather than financial: a listed healthcare manufacturer with a recurring compliance record, in a sector where the State Securities Commission and exchange disclosure rules increasingly scrutinize governance and internal controls.

Strategic Significance

For long-term investors, the fine is not the issue — VND 160 million is negligible against Traphaco’s operating scale. The issue is the pattern. Three separate manufacturing violations, each escalated to the maximum penalty bracket for repeat and large-scale conduct, sit alongside tax penalties in 2018, 2023 and 2026. That recurrence points to weaknesses in regulatory affairs and quality-assurance processes at a company whose brand equity rests on GMP-certified production and trusted herbal and generic medicines. In Vietnam’s pharmaceutical sector, where tender participation, hospital listings and export registration depend on clean regulatory records, repeated findings can raise the cost of compliance and slow product approvals over time.

What to Watch

• Whether the Drug Administration or Ministry of Health opens a broader inspection of Traphaco’s manufacturing sites or product dossiers.
• Any disclosure from Traphaco on corrective actions, quality-assurance staffing or regulatory-affairs procedures.
• The company’s next annual or semi-annual report for updated compliance and internal-control disclosures.
• Whether the affected products — Piracetam 400mg, Methorphan, Nostravin and Loratadin 10mg — face tender or distribution restrictions.
• Follow-up tax inspection outcomes, given the February 2026 penalty of approximately VND 3.3 billion.